Agios Pharmaceuticals Inc. (AGIO) and Blueprint Medicines Corporation (NASDAQ:BPMC) Contrasting side by side

We are comparing Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Blueprint Medicines Corporation (NASDAQ:BPMC) on their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agios Pharmaceuticals Inc. 94.39M 40.22 346.03M -6.03 0.00
Blueprint Medicines Corporation 44.52M 84.93 236.64M -5.39 0.00

Table 1 demonstrates Agios Pharmaceuticals Inc. and Blueprint Medicines Corporation’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Agios Pharmaceuticals Inc. and Blueprint Medicines Corporation.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals Inc. -366.60% -44.1% -36.2%
Blueprint Medicines Corporation -531.54% -46.6% -38.2%

Risk & Volatility

Agios Pharmaceuticals Inc. is 140.00% more volatile than Standard & Poor’s 500 due to its 2.4 beta. Competitively, Blueprint Medicines Corporation is 59.00% more volatile than Standard & Poor’s 500, because of the 1.59 beta.

Liquidity

The Current Ratio of Agios Pharmaceuticals Inc. is 6.6 while its Quick Ratio stands at 6.6. The Current Ratio of rival Blueprint Medicines Corporation is 8.3 and its Quick Ratio is has 8.3. Blueprint Medicines Corporation is better equipped to clear short and long-term obligations than Agios Pharmaceuticals Inc.

Analyst Ratings

Recommendations and Ratings for Agios Pharmaceuticals Inc. and Blueprint Medicines Corporation can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Agios Pharmaceuticals Inc. 0 0 2 3.00
Blueprint Medicines Corporation 0 0 1 3.00

Agios Pharmaceuticals Inc.’s upside potential currently stands at 19.21% and an $77.5 average target price. On the other hand, Blueprint Medicines Corporation’s potential upside is 22.46% and its average target price is $105. The results from earlier shows that analysts belief suggest that Blueprint Medicines Corporation seems more appealing than Agios Pharmaceuticals Inc.

Institutional & Insider Ownership

0.3% are Agios Pharmaceuticals Inc.’s share owned by insiders. Comparatively, Blueprint Medicines Corporation has 0.1% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Agios Pharmaceuticals Inc. 8.26% 25.93% -1.33% -15% -17.41% 46.39%
Blueprint Medicines Corporation 9.38% 17.78% 50.39% 14.54% -5.66% 57.5%

For the past year Agios Pharmaceuticals Inc.’s stock price has smaller growth than Blueprint Medicines Corporation.

Summary

Blueprint Medicines Corporation beats on 6 of the 11 factors Agios Pharmaceuticals Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase (NTRK) and predicted NTRK resistant mutants. In addition, the company is developing treatments that target cancer and rare genetic diseases. The company has agreements with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.